Concepts aimed at improving pharmaceutical care for patients with socially significant diseases in Russia and worldwide
https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.325
Abstract
Objective: To conduct a comparative analysis of concepts aimed at improving pharmaceutical care for patients with socially significant diseases in both Russia and other countries with the purpose of identifying priority development directions for the Russian system.
Material and methods. A systematic search of scientific literature, regulatory documents, and statistical data for 2016–2025 was conducted using the PubMed/MEDLINE, CyberLeninka, and eLibrary databases. A comparative method was applied to analyze European, North American, and Russian pharmaceutical provision models. Their effectiveness was evaluated based on accessibility, financial sustainability, quality of care, and innovation criteria.
Results. The European model is characterized by a high level of government funding (70–80%) and effective cost control mechanisms through health technology assessment institutions. The North American system demonstrates trends toward universal coverage with multiple funding sources. The Russian model provides 100% coverage for high-cost nosologies, however, the overall share of government funding reaches 40% with a significant regional differentiation in accessibility. Current trends include implementation of personalized medicine, targeted therapy, telemedicine, and risk-sharing agreements with pharmaceutical companies.
Conclusion. Priority directions for improving the Russian system include unification of regional approaches, implementation of clinical and economic effectiveness assessment mechanisms, development of personalized medicine and digital technologies for pharmaceutical care management.
About the Authors
Yu. Sh. Gushchina
Peoples' Friendship University of Russia named after Patrice Lumumba
Russian Federation
Russian Federation
Yulia Sh. Gushchina, Assoc. Prof.
6 Miklukho-Maklay Str., Moscow 117198
A. Yu. Abramov
Peoples' Friendship University of Russia named after Patrice Lumumba
Russian Federation
Russian Federation
Aleksey Yu. Abramov, Dr. Sci. Med., Prof.
6 Miklukho-Maklay Str., Moscow 117198
References
1. Воропинова О.А., Киселева И.Н., Нестеренко А.В. Социально значимые заболевания: динамические характеристики, факторы роста, проблемы учета и управления. Economics: Yesterday, Today and Tomorrow. 2023; 13 (11-1): 357–70 (in Russ.).
2. Grinin L.E., Grinin A.L., Korotayev A.V. Aging of the global population as an integral problem of the future. Sociological Journal. 2023; 29 (2): 110–31 (in Russ.). https://doi.org/10.19181/socjour.2023.29.2.6.
3. Henman M.C., Ravera S., Lery F.X. Council of Europe Resolution on the Implementation of Pharmaceutical Care – a step forward in enhancing the appropriate use of medicines and patient-centred care. Healthcare. 2024; 12 (2): 232. https://doi.org/10.3390/healthcare12020232.
4. Flessa S., Huebner C. Innovations in health care – a conceptual framework. Int J Environ Res Public Health. 2021; 18 (19): 10026. https://doi.org/10.3390/ijerph181910026.
5. Orhan R., Paric M., Czabanowska K. Lessons learnt from the EU response to NCDs: a content analysis on building resilient post-COVID health systems. Healthcare. 2021; 9 (12): 1659. https://doi.org/10.3390/healthcare9121659.
6. Vallano A., Pontes C., Agustí A. The challenges of access to innovative medicines with limited evidence in the European Union. Front Pharmacol. 2023; 14: 1215431. https://doi.org/10.3389/fphar.2023.1215431.
7. European Parliamentary Research Service. Improving access to medicines and promoting pharmaceutical information. Available at: https://www.europarl.europa.eu/RegData/etudes/STUD/2023/753166/EPRS_STU(2023)753166_EN.pdf (accessed 10/06/2025).
8. Canfell O.J., Davidson K., Woods L., et al. Precision public health for non-communicable diseases: an emerging strategic roadmap and multinational use cases. Front Public Health. 2022; 10: 854525. https://doi.org/10.3389/fpubh.2022.854525.
9. Budreviciute A., Damiati S., Sabir D.K., et al. Management and prevention strategies for non-communicable diseases (NCDs) and their risk factors. Front Public Health. 2020; 8: 574111. https://doi.org/10.3389/fpubh.2020.574111.
10. Santiago A. Healthy China 2030: a plan towards growth, development and innovation in health sector. 2021. Available at: https://www.researchgate.net/publication/348603525_Healthy_China_2030_a_plan_towards_growth_development_and_innovation_in_health_sector (accessed 11.06.2025).
11. Hu M., Hao Z., Yin Y. Promoting the integration of elderly healthcare and elderly nursing: evidence from the Chinese government. Int J Environ Res Public Health. 2022; 19 (24): 16379. https://doi.org/10.3390/ijerph192416379.
12. Yang Y., Meng Y. Is China moving toward healthy aging? A tracking study based on 5 phases of CLHLS data. Int J Environ Res Public Health. 2020; 17 (12): 4343. https://doi.org/10.3390/ijerph17124343.
13. Krings M.F., van Wijngaarden J.D., Yuan S., Huijsman R. China's elder care policies 1994–2020: a narrative document analysis. Int J Environ Res Public Health. 2022; 19 (10): 6141. https://doi.org/10.3390/ijerph19106141.
14. Bhuiyan M.A., Galdes N., Cuschieri S., et al. A comparative systematic review of risk factors, prevalence, and challenges contributing to non-communicable diseases in South Asia, Africa, and Caribbeans. J Health Popul Nutr. 2024; 43: 140. https://doi.org/10.1186/s41043-024-00607-2.
15. Owusu M.F., Adu J., Dortey B.A., et al. Exploring health promotion efforts for non-communicable disease prevention and control in Ghana. PLoS Glob Public Health. 2023; 3 (9): e0002408. https://doi.org/10.1371/journal.pgph.0002408.
16. Niohuru I. Healthcare and disease burden in Africa: the impact of socioeconomic factors on public health. Disease burden and mortality. Springer; 2023: 35–85. https://doi.org/10.1007/978-3-031-19719-2_3.
17. Bykova A.V., Solodukhin K.S. Problems of healthcare financial support and investment in public health. Creative Economy. 2022; 16 (2): 717–38 (in Russ.). https://doi.org/10.18334/ce.16.2.114188.
18. Zeeb H., Loss J., Starke D., et al. Public health in Germany: structures, dynamics, and ways forward. Lancet Public Health. 2025; 10 (4): e333–42. https://doi.org/10.1016/S2468-2667(25)00033-7.
19. Jakubowski S., Holko P., Nowak R., et al. Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries. Front Pharmacol. 2024; 15: 1498386. https://doi.org/10.3389/fphar.2024.1498386.
20. Gerkens S., Merkur S. Belgium: health system review. Health Syst Transit. 2020; 22 (5): 1–237.
21. Kruk M.E., Gage A.D., Arsenault C., et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. Lancet Glob Health. 2018; 6 (11): e1196–252. https://doi.org/10.1016/S2214-109X(18)30386-3.
22. Hanson K., Brikci N., Erlangga D., et al. The Lancet Global Health Commission on financing primary health care: putting people at the centre. Lancet Glob Health. 2022; 10 (5): e715–72. https://doi.org/10.1016/S2214-109X(22)00005-5.
23. Grechushkina N.A. Management economics at the primary health care level in foreign countries: expert review. Available at: https://niioz.ru/upload/iblock/ae4/ae4be27cb9c56eed576043ce86cae506.pdf (in Russ.) (accessed 11.06.2025).
24. Docteur E., Landers R.M., Cole B., et al. Examining approaches to expand medicare eligibility: key design options and implications. Available at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550074 (accessed 11.06.2025).
25. Crowley R., Daniel H., Cooney T.G., et al. Envisioning a better U.S. health care system for all: coverage and cost of care. Ann Intern Med. 2020; 172 (2 Suppl.): S7–32. https://doi.org/10.7326/M19-2415.
26. Sorum P.C., Stein C., Moore D.L. “Comprehensive Healthcare for America”: using the insights of behavioral economics to transform the U.S. Healthcare System. J Law Med Ethics. 2023; 51 (1): 153–71. https://doi.org/10.1017/jme.2023.52.
27. Martinez R.M., Osei-Anto H.A., McCormick M. (Eds) Addressing sickle cell disease: a strategic plan and blueprint for action. Washington (DC): National Academies Press (US), 2020. Available at: https://www.ncbi.nlm.nih.gov/books/NBK566454 (accessed 11.06.2025).
28. Singh Thakur J., Nangia R., Singh S. Progress and challenges in achieving noncommunicable diseases targets for the sustainable development goals. FASEB Bioadv. 2021; 3 (8): 563–8. https://doi.org/10.1096/fba.2020-00117.
29. Japan Health System Review. Health Syst Transit. 2018; 8 (1): 1–248.
30. Ji S., Lee M., Choi M., Park S. The impact of the expanded health insurance coverage policy on healthcare spending: evidence from Korea. Int J Equity Health. 2024; 23 (1): 126. https://doi.org/10.1186/s12939-024-02206-3.
31. Bloom D.E., Chen S., Kuhn M., et al. The economic burden of chronic diseases: Estimates and projections for China, Japan, and South Korea. J Econ Ageing. 2020; 17: 100163. https://doi.org/10.1016/j.jeoa.2018.09.002.
32. Durizzo K., Harttgen K., Tediosi F., et al. Toward mandatory health insurance in low-income countries? An analysis of claims data in Tanzania. Health Econ. 2022; 31 (10): 2187–207. https://doi.org/10.1002/hec.4568.
33. Yenet A., Nibret G., Tegegne B.A. Challenges to the availability and affordability of essential medicines in African countries: a scoping review. Clinicoecon Outcomes Res. 2023; 15: 443–58. https://doi.org/10.2147/CEOR.S413546.
34. Karamagi H.C., Njuguna D., Kidane S.N., et al. Financing health system elements in Africa: a scoping review. PLoS One. 2023; 18 (9): e0291371. https://doi.org/10.1371/journal.pone.0291371.
35. Telnova E.A. Organization of drug supply in the Russian Federation. Bulletin of Semashko National Research Institute of Public Health. 2021; 1: 100–11 (in Russ.). https://doi.org/10.25742/NRIPH.2021.01.013.
36. Takawira B., Pooe D., Samuels A. Assessing disruptions in pharmaceutical supply chains: a qualitative study of resilience and risks in the South African context. J Econ Soc Develop. 2024; 11 (2): 43–62.
37. Jailobaeva K., Falconer J., Loffreda G., et al. An analysis of policy and funding priorities of global actors regarding noncommunicable disease in low- and middle-income countries. Global Health. 2021; 17 (1): 68. https://doi.org/10.1186/s12992-021-00713-4.
38. Adebisi Y.A., Nwogu I.B., Alaran A.J., et al. Revisiting the issue of access to medicines in Africa: challenges and recommendations. Public Health Chall. 2022; 1 (2): e9. https://doi.org/10.1002/puh2.9.
39. Овод А.И. Финансирование системы лекарственного обеспечения Российской Федерации. Иннов: электронный научный журнал. 2017; 4. Ovod A.I. Financing of pharmaceutical supply systems of the Russian Federation. Innov: Electronic Scientific Journal. 2017; 4 (in Russ.).
40. Ulumbekova G.E., Medik V.A. (Eds) Public health and healthcare. National guide. Chapter 16. Drug supply of the population in the Russian Federation. Moscow: GEOTAR-Media; 2022: 1144 pp. (in Russ.).
41. Soboleva E.A. The budgetary and insurance model of healthcare funding in Russia. Finance: Theory and Practice. 2021; 25 (3): 127–49 (in Russ.). https://doi.org/10.26794/2587-5671-2021-25-3-127-149.
42. Petrov A.G., Khoroshilova O.V., Filimonov S.N., Semenikhin V.A. Methodological foundations of the organization specialized pharmaceutical care for patients with socially significant diseases. Medicine in Kuzbass. 2025; 24 (1): 77–82 (in Russ.). https://doi.org/10.24412/2687-0053-2025-1-77-82.
43. Toluzakov A.K. Current trends and threats in the provision of medicines to the population of Russia. KANT. 2021; 2: 106–10 (in Russ.).
44. Aghajanyan S., Karapetyan L., Petrosyan A., et al. The necessity of introduction the drug insurance system in Armenia. World Science. 2022; 5: 67–75. https://doi.org/10.31435/rsglobal_ws/30092022/7871.
45. Or Z., Gandré C., Seppänen A.V., et al. France: health system review. Health Syst Transit. 2023; 25 (3): 1–276.
46. Kalashnikov K.N. Conceptualizing the notion of “socially significant diseases” in strategic planning. Economic and Social Changes: Facts, Trends, Forecast. 2024; 17 (2): 187–201. https://doi.org/10.15838/esc.2024.2.92.10.
47. Shevchenko S.B., Puzin S.N., Shurgaya M.A., Osadchuk M.A. Socially significant diseases in the disability nosological structure in the elderly in the Russian Federation. Sechenov Medical Journal. 2016; 3: 4–11 (in Russ.).
48. Marques L., Costa B., Pereira M., et al. Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics. 2024; 16 (3): 332. https://doi.org/10.3390/pharmaceutics16030332.
49. Vudathaneni V.K.P., Lanke R.B., Mudaliyar M.C., et al. The impact of telemedicine and remote patient monitoring on healthcare delivery: a comprehensive evaluation. Cureus. 2024; 16 (3): e55534. https://doi.org/10.7759/cureus.55534.
50. Timerbulatova L.I. Priority directions of state policy in the sphere of health care. Molodoy uchenyy / Young Scientist. 2017; 40: 140–2 (in Russ.).
What is already known about thе subject?
► Drug provision models vary significantly from country to country. Systems supported by a high level of public funding and uniform standards of accessibility demonstrate the highest effectiveness
► The integration of primary health care with drug provision programs contributes to raising patient compliance to treatment and improving control over chronic diseases
► Personalized medicine and digital technologies are increasingly being introduced into the healthcare system to improve its quality and effectiveness
What are the new findings?
► For the first time, a systematic comparative review of concepts aimed at improving medical care for socially significant diseases in Russia and abroad was conducted. Priorities for adapting international practices to the Russian healthcare model was identified
► Priority areas for development include standardization of approaches, introduction of clinical and economic effectiveness assessment, and digitalization of drug provision management
How might it impact the clinical practice in the foreseeable future?
► The use of clinical and economic effectiveness assessment systems will enable physicians to prescribe only those drugs which demonstrate proven effectiveness at optimal costs. This is particularly important in the treatment of high-cost diseases, such as cancer and multiple sclerosis
► The introduction of electronic prescriptions and remote monitoring platforms will make it possible to track patient compliance to treatment, monitor side effects, and timely adjust therapy, which is of particular importance in remote regions with limited access to specialized care
Review
For citations:
Gushchina Yu.Sh., Abramov A.Yu. Concepts aimed at improving pharmaceutical care for patients with socially significant diseases in Russia and worldwide. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2026;1(19):200-210. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.325
Views:
589
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 